QS Investors’s Agios Pharmaceuticals AGIO Stock Holding History

QS Investors’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,500	Closed	-$81K	–	1180
2020 Q2	$81K	Hold	1,500	–	–	﹤0.01%	1375
2020 Q1	$54K	Hold	1,500	–	–	﹤0.01%	1392
2019 Q4	$72K	Hold	1,500	–	–	﹤0.01%	1439
2019 Q3	$49K	Hold	1,500	–	–	﹤0.01%	1478
2019 Q2	$75K	Hold	1,500	–	–	﹤0.01%	1446
2019 Q1	$102K	Sell	1,500 -13	-0.9%	-$757	﹤0.01%	1398
2018 Q4	$70K	Hold	1,513	–	–	﹤0.01%	1403
2018 Q3	$117K	Hold	1,513	–	–	﹤0.01%	1358
2018 Q2	$127K	Buy	1,513 +13	+0.9%	+$1.13K	﹤0.01%	1348
2018 Q1	$123K	Sell	1,500 -1,300	-46%	-$100K	﹤0.01%	1326
2017 Q4	$160K	Hold	2,800	–	–	﹤0.01%	1281
2017 Q3	$187K	Hold	2,800	–	–	﹤0.01%	1250
2017 Q2	$144K	Buy	+2,800	New	+$143K	﹤0.01%	1323
2016 Q1	–	Sell	-4	Closed	-$1K	–	1978
2015 Q4	$1K	Buy	+4	New	+$262	﹤0.01%	1535

Other funds holding AGIO

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

QS Investors's AGIO Position: Q3 2020 in Review

QS Investors sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 1,500 shares — an estimated $81K sold.

QS Investors first reported a position in AGIO in Q4 2015 and held it in 14 quarters. The position peaked at $187K in Q3 2017. 215 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

QS Investors reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
QS Investors sold 1,500 Agios Pharmaceuticals shares in Q3 2020, an estimated $81K.
QS Investors first reported a position in Agios Pharmaceuticals in Q4 2015 and held it in 14 quarters.
QS Investors's Agios Pharmaceuticals position peaked at $187K in Q3 2017.
215 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.